| Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ... New England Journal of Medicine 373 (25), 2425-2437, 2015 | 1571 | 2015 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 793 | 2019 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 394 | 2016 |
| Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia RT Swords, KR Kelly, PG Smith, JJ Garnsey, D Mahalingam, E Medina, ... Blood, The Journal of the American Society of Hematology 115 (18), 3796-3800, 2010 | 281 | 2010 |
| STI571: a paradigm of new agents for cancer therapeutics MJ Mauro, M O’Dwyer, MC Heinrich, BJ Druker Journal of clinical oncology 20 (1), 325-334, 2002 | 269 | 2002 |
| COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with … D Zhang, R Guo, L Lei, H Liu, Y Wang, Y Wang, H Qian, T Dai, T Zhang, ... MedRxiv, 2020.03. 24.20042655, 2020 | 221 | 2020 |
| Glycosylation-based serum biomarkers for cancer diagnostics and prognostics A Kirwan, M Utratna, ME O’Dwyer, L Joshi, M Kilcoyne BioMed research international 2015, 2015 | 204 | 2015 |
| The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML ME O'Dwyer, MJ Mauro, G Kurilik, M Mori, S Balleisen, S Olson, ... Blood, The Journal of the American Society of Hematology 100 (5), 1628-1633, 2002 | 197 | 2002 |
| Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma L Vincenz, R Jäger, M O'Dwyer, A Samali Molecular cancer therapeutics 12 (6), 831-843, 2013 | 183 | 2013 |
| Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate ME O'Dwyer, MJ Mauro, C Blasdel, M Farnsworth, G Kurilik, YC Hsieh, ... Blood 103 (2), 451-455, 2004 | 181 | 2004 |
| International evolution of fat, oil and grease (FOG) waste management–A review T Wallace, D Gibbons, M O'Dwyer, TP Curran Journal of environmental management 187, 424-435, 2017 | 180 | 2017 |
| Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes D Zhang, R Guo, L Lei, H Liu, Y Wang, Y Wang, H Qian, T Dai, T Zhang, ... Journal of Leucocyte Biology 109 (1), 13-22, 2021 | 152 | 2021 |
| Clinical utility of PET/CT in lymphoma CG Cronin, R Swords, MT Truong, C Viswanathan, E Rohren, FJ Giles, ... American Journal of Roentgenology 194 (1), W91-W103, 2010 | 144 | 2010 |
| Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate ME O'Dwyer, KM Gatter, M Loriaux, BJ Druker, SB Olson, RE Magenis, ... Leukemia 17 (3), 481-487, 2003 | 143 | 2003 |
| Clonal evolution in chronic myelogenous leukemia J Cortes, ME O'Dwyer Hematology/Oncology Clinics 18 (3), 671-684, 2004 | 137 | 2004 |
| Recent advancements in the treatment of chronic myelogenous leukemia ME O'Dwyer, MJ Mauro, BJ Druker Annual review of medicine 53 (1), 369-381, 2002 | 135 | 2002 |
| Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia FJ Giles, M O'dwyer, R Swords Leukemia 23 (10), 1698-1707, 2009 | 133 | 2009 |
| In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia P La Rosée, K Johnson, ME O'Dwyer, BJ Druker Experimental hematology 30 (7), 729-737, 2002 | 130 | 2002 |
| Hematopathologic and cytogenetic findings in imatinib mesylate–treated chronic myelogenous leukemia patients: 14 months' experience RM Braziel, TM Launder, BJ Druker, SB Olson, RE Magenis, MJ Mauro, ... Blood, The Journal of the American Society of Hematology 100 (2), 435-441, 2002 | 129 | 2002 |
| Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised … T Facon, SK Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... The Lancet Oncology 22 (11), 1582-1596, 2021 | 123 | 2021 |
